Ciloa Revenue and Competitors
Estimated Revenue & Valuation
- Ciloa's estimated annual revenue is currently $2.3M per year.
- Ciloa's estimated revenue per employee is $155,000
Employee Data
- Ciloa has 15 Employees.
- Ciloa grew their employee count by -6% last year.
Ciloa Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Ciloa?
CILOA'S CUSTOMIZED EXOSOMES FOR INNOVATIVE THERAPEUTICS Ciloa is the most experienced exosome-based R&D Company dedicated to the development of new high-potential bio-drugs. By overcoming undruggable targets, Ciloa supports your projects to create new therapeutic and new preventive solutions. Ciloa customizes in vivo exosomes to contain i) fully native membrane protein complexes (GPCRs, Kinase Receptors, Ion Channels, Viral Antigens, Transporters…) embedded in their membrane and ii) chosen cargo proteins inside their cytosol. Natural properties of exosomes combined with Ciloa in vivo disruptive technology allow to develop: - VIRUS-FREE candidate THERAPEUTIC VECTORS able to deliver specifically chosen cargos to any diseased organ. - ANTIBODIES AGAINST UNDRUGGABLE MEMBRANE PROTEIN COMPLEX TARGETS by unlocking all bottlenecks of the antibody development process. - ADJUVANT & VIRUS-FREE candidate VACCINES, thanks to the combination of perfect antigens with the potent natural adjuvant properties of exosomes. Ciloa works through Licensing and Partnerships.
keywords:N/A
N/A
Total Funding
15
Number of Employees
$2.3M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Ciloa News
La biotech Ciloa a levé 5 M pour développer de nouveaux vaccins utilisant les exosomes. Une technologie qui vise plusieurs virus : Covid-19...
Ciloa is a French biotech company, spin-off of the CNRS and the University of Montpellier, pioneer in the development of vaccines and exosome-...
Other Companies in Montpellier
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.3M | 15 | 7% | N/A |
#2 | $1.4M | 16 | N/A | N/A |
#3 | $2.4M | 16 | -6% | N/A |
#4 | $2.7M | 18 | -18% | N/A |
#5 | $1.7M | 19 | 6% | N/A |